Venezuelan equine encephalitis

Summary

Venezuelan equine encephalitis (MONDO:0006005) is a disease and 3 clinical trials. A subtype of encephalomyelitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Venezuelan equine encephalitis
Mondo ID	MONDO:0006005
EFO	EFO:0007534
MeSH	D004685
DOID	DOID:9584
ICD-10-CM	A92.2
ICD-11	608978790
NCIT	C35121
SNOMED CT	417067005
UMLS	C0014078
MedGen	4036
GARD	0006355
Is cancer (heuristic)	no

Also known as: Venezuelan equine encephalitis virus caused disease or disorder · Venezuelan equine encephalitis virus disease or disorder · Venezuelan equine encephalitis virus infectious disease · Venezuelan equine fever

Disease family

This is a subtype of encephalomyelitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › Venezuelan equine encephalitis

Related subtypes (6): myelitis, cerebritis, optic neuritis, encephalitis, meningitis, hypophysitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07088822	PHASE1	NOT_YET_RECRUITING	A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
NCT00109304	PHASE1	WITHDRAWN	Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine
NCT03879603	PHASE1	COMPLETED	VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults